TABLE 3.
Oncologic characteristics
| Primary tumor site, n (%) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oropharyngeal |
||||||||||
| Author (year) | N | Pharyngeal | All | Eval | HPV+ | HPV− | Nasal cavity | Oral cavity | Laryngeal | Other |
| Cohen (2019) | 247 | a | NA | NA | NA | NA | a | a | a | a |
| Zandberg (2019) | 112 | 40 (36) | 40 | 37 | 20 | 17 | 0 | 47 (39) | 15 (13) | 1 (1) |
| Colevas (2018) | 32 | 23 (72) | 18 | 16 | 12 | 4 | 0 | 7 (22) | 2 (6) | 0 |
| Ferris (2018)b | 240 | 92 (38) | NA | NA | NA | NA | 0 | 108 (45) | 34 (14) | 6 (3) |
| Mehra (2018)b | 192 | 97 | 76 | NA | NA | NA | 12 | 28 | 18 | 37 |
| Siu (2018) | 67 | 33 (49) | 25 | NA | NA | NA | 0 | 15 (22) | 17 (25) | 0 |
| Bauml (2017) | 171 | 108 (63) | 100 | NA | NA | NA | 1 (1) | 28 (16) | 30 (18) | 0 |
| Hsu (2017) | 27 | 27 (100) | NA | NA | NA | NA | 0 | 0 | 0 | 0 |
Abbreviations: CPS, Combined Positive Score; if more than one methodology was reported, Combined Positive Score ≥ 1 was determined to indicated positivity; Eval, evaluable; IC, area of tumor area positive for immune cells; NA, not available; TC, tumor cell staining.
a
Not reported or not tested.
b
Data from most recent study are presented here; if data in most recent study were not specifically reported, then data from prior studies are reported.